25
Participants
Start Date
June 30, 2010
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Sorafenib
Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
Cisplatin
75 mg/m² given IV
Paclitaxel
175 mg/m² given IV
Grady Memorial Hospital, Atlanta
Emory University Hospital Midtown, Atlanta
Emory University Winship Cancer Institute, Atlanta